Walter Eisner • Thu, May 29th, 2014
Print this article
Medtronic Inc.’s overall spine sales declined by 2% to $786 million during the company’s previous quarter.
During a call with Wall Street analysts on May 20, 2014, company leaders said with core spine sales growing, they are counting on the stabilization of kyphoplasty and Infuse to get them back to overall growth.
Core Spine Business Growing
Excluding sales of balloon kyphoplasty (BKP), company management reported that its core spine business grew by 1% to $662 million in a spine market that remained relatively flat on a year-over-year basis. Infuse sales of $124 million declined 11% due to difficult comparisons following the resolution of a supply disruption in the prior year. An Infuse liability settlement also impacted net earnings.
